In the human prostate gland, several progestins, including chlormadinone, and osaterone, were found to reduce the volume of benign prostatic hyperplasia (BPH) mass due to shrinkage of glandular and stromal compartments by antagonizing the AR signaling pathway [13,14]. Here, AR is linked to benign prostatic hyperplasia.